Effect of the lysosomal membrane protein LAMP2 repression on resistance to front-line therapies in myelodysplastic syndromes and acute myeloid leukemia.

assignment_turned_inprojectUntil08 Dec 2022Closed

Funder: Institut National du CancerProject code: INCa-13839 Call for proposal: PLBIO19

Funded under: PLBIO

Effect of the lysosomal membrane protein LAMP2 repression on resistance to front-line therapies in myelodysplastic syndromes and acute myeloid leukemia.

- Summary
- DMPs

Partners

CNRS UMR7212 - INSERM U944 , INSERM U1065

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::c6f373c70d508f031d04657d7c8a8cb3&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Effect of the lysosomal membrane protein LAMP2 repression on resistance to front-line therapies in myelodysplastic syndromes and acute myeloid leukemia.

Effect of the lysosomal membrane protein LAMP2 repression on resistance to front-line therapies in myelodysplastic syndromes and acute myeloid leukemia.

Loading